NOVABIO Research Profile

What Is Melanotan I (MT-1)?

Melanotan I (MT-1) is a peptide entry commonly identified by the Melanotan I and MT-1 names. This page identifies the material as Melanotan I (MT-1), with amino acid count 13; synonyms Afamelanotide; [Nle4-D-Phe7]-α-MSH. The Melanotan I (MT-1) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Exact-product regulatory reviewLast verified 2026-10-06
Catalogue identityMelanotan I (MT-1)
Available specifications10mg
Evidence snapshot0 trials · 19 publications
Last verified2026-10-06

What Is Melanotan I (MT-1)?

Melanotan I (MT-1) is a peptide entry commonly identified by the Melanotan I and MT-1 names. This page identifies the material as Melanotan I (MT-1), with amino acid count 13; synonyms Afamelanotide; [Nle4-D-Phe7]-α-MSH. The Melanotan I (MT-1) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

0ClinicalTrials.gov query records
19PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Melanotan I (MT-1) is organized around melanocortin receptor research, peptide ligand profiling, signal-response studies, and analytical peptide workflows. For Melanotan I (MT-1), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Use of melanotan I and II in the general population.

BMJ (Clinical research ed.) · 2009 Feb 17

PMID 19224885
Selected PubMed record

Discovery and development of novel melanogenic drugs. Melanotan-I and -II.

Pharmaceutical biotechnology · 1998

PMID 9760697
Selected PubMed record

[Undesirable pigmentation].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2015 Oct

PMID 26315100
Selected PubMed record

Skin pigmentation and pharmacokinetics of melanotan-I in humans.

Biopharmaceutics & drug disposition · 1997 Apr

PMID 9113347
Selected PubMed record

A glimpse into the underground market of melanotan.

Dermatology online journal · 2018 May 15

PMID 30142729
Selected PubMed record

Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.

Pharmaceutical research · 2000 May

PMID 10888312

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
Melanotan I (MT-1)
Available Specifications
10mg
Pack Format
10 Vials
CAS Number
75921-69-6
Molecular Formula
C78H111N21O19
Molecular Weight
1646.87 g/mol
Amino Acid Count
13
Sequence
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Synonyms
Afamelanotide; [Nle4-D-Phe7]-α-MSH
Physical Form
Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 16197727 · Product form must still be matched to the catalogue and batch record.

Research Tools for Melanotan I (MT-1)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Melanotan I (MT-1) Research Summary

Identity

Melanotan I (MT-1); specifications: 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for Melanotan I (MT-1) is organized around melanocortin receptor research, peptide ligand profiling, signal-response studies, and analytical peptide workflows. For Melanotan I (MT-1), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

0 registry records and 19 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Melanotan I (MT-1) is represented here by the catalogue identity Melanotan I (MT-1). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Melanotan I (MT-1) is organized around melanocortin receptor research, peptide ligand profiling, signal-response studies, and analytical peptide workflows. For Melanotan I (MT-1), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 19 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Melanotan I (MT-1) FAQ

What is Melanotan I (MT-1)?

Melanotan I (MT-1) is a peptide entry commonly identified by the Melanotan I and MT-1 names. This page identifies the material as Melanotan I (MT-1), with amino acid count 13; synonyms Afamelanotide; [Nle4-D-Phe7]-α-MSH. The Melanotan I (MT-1) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Melanotan I (MT-1)?

The synchronized query returned 0 ClinicalTrials.gov records and 19 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Melanotan I (MT-1) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.